Allarity Therapeutics reports two ovarian cancer patients exceed one year on stenoparib therapy

Allarity Therapeutics, Inc.

Two patients in Phase 2 trial for advanced recurrent ovarian cancer have exceeded one year on stenoparib.
Patients pre-screened using DRP companion diagnostic; show durable clinical benefit in heavily pre-treated population.
One confirmed complete response and long-term disease stability observed.
CEO notes extending life by 52 weeks is noteworthy for heavily pre-treated patients.
Company planning next phase of development, accelerating path toward regulatory approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.